Medical Developments International Limited · ASX:MVP
Medical Developments International — Bell Potter Healthcare Conference 2024
10 slides from Medical Developments International's conference presentation, Nov 20, 2024
Slide 1: Bell Potter Healthcare Conference
ASX:MVP For personal use only Medical Developments International Bell Potter Healthcare Conference November 2024 Brent MacGregor, CEO
Slide 2: Important notice and disclaimer
Important notice and disclaimer This presentation contains summary information about Medical Developments International Limited (ACN 108340667) and its related bodies corporate (together, MVP) and MVP’s activities as at the date of this presentation. It is information given in summary form only and
Slide 3: Important notice and disclaimer
Important notice and disclaimer Factors that could cause actual results to differ materially include: • the success of research and development activities (including clinical trials); • decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label
Slide 4: For personal use only
Medical Developments International ASX: MVP | market capitalisation $50 million | revenue $33.2 million in FY24 | cash balance $16 million Pain Management Respiratory For personal use only Supplies pharmacies, medical clinics and hospitals with a range of Description Manufactures Penthrox®, an inhal
Slide 5: Positive momentum
Positive momentum Well-positioned for future growth Deep penetration of Penthrox in Australian ambulance Penthrox, the iconic Green Whistle For personal use only Growing use of Penthrox in hospital emergency departments Penthrox® distributed in more than 20 international markets Successful c
Slide 6: Market potential of Penthrox
Market potential of Penthrox Clearer understanding of how to drive growth sustainably Australia International Procedural ✓ Penthrox® used broadly in 100% of ambulance ✓ Distributed in more than 20 international ✓ Procedural indication in Australia and For personal use only bodies in Australia market
Slide 7: Accelerating market penetration
Accelerating market penetration Opportunity to grow in existing markets, with potential to enter new markets in the future Our strategy to accelerate penetration • Reduce field-based commercial investment in the near term, in favour of increased medical For personal use only engagement • Engage with
Slide 8: The MAGPIE study – a growth enabler
The MAGPIE study – a growth enabler A successful clinical study outcome in children1,2 potentially expands addressable market for Penthrox • Submission of the MAGPIE study data to the European regulatory agency For personal use only in August 2024 • Regulatory approval of a reduced age indication in
Slide 9: FY25 priorities
FY25 priorities Deliver improved earnings and cashflow and accelerate product penetration FY25 strategic priorities For personal use only Continue to improve margins through pricing and operational efficiency Accelerate penetration of Penthrox in Australia Grow Penthrox in global markets Drive conti
Slide 10: For personal use only
ASX:MVP For personal use only Medical Developments International
Medical Developments International — Bell Potter Healthcare Conference 2024 on 6ix